Clinical Trials Search Tool
ATH-1017 for Treatment of Mild to Moderate Alzheimer’s Disease
Disease/Condition: Alzheimer’s disease
Location: Portland
Ages: 55-85
Enrollment Opens: 12-01-2021
Enrollment Closes: TBD
More info »
A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants with Early Alzheimer’s Disease
Disease/Condition: Alzheimer’s disease
Location: Portland
Ages: 50-85
Enrollment Opens: 04-01-2022
Enrollment Closes: TBD
More info »
Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer’s Disease
Disease/Condition: Alzheimer’s disease
Location: Portland
Ages: 50-87
Enrollment Opens: 04-01-2022
Enrollment Closes: TBD
More info »
A Research Study Investigating Semaglutide in People With Early Alzheimer’s Disease
Disease/Condition: Alzheimer’s disease
Location: Portland
Ages: 55-85
Enrollment Opens: 04-01-2022
Enrollment Closes: TBD
More info »
A trial of oral Semaglutide in patients with early Alzheimer’s Disease (EVOKE)
Disease/Condition: Alzheimer’s disease
Location: Portland
Ages: 55-85
Enrollment Opens: 01-31-2022
Enrollment Closes: TBD
More info »
A trial of oral Semaglutide in patients with early Alzheimer’s Disease who also exhibit MRI evidence of cerebrovascular disease (EVOKE PLUS)
Disease/Condition: Alzheimer’s disease
Location: Portland
Ages: 55-65
Enrollment Opens: 01-31-2022
Enrollment Closes: TBD
More info »
AHEAD 3-45 Study: A clinical trial to evaluate the efficacy and safety of treatment with BAN 2401 in patients with pre-clinical Alzheimer’s Disease risk factors
Disease/Condition: Alzheimer’s disease
Location: Portland
Ages: 50-80
Enrollment Opens: 11/03/2020
Enrollment Closes: TBD
More info »
ATHIRA 0201~A randomized, placebo controlled study of ATH-1017 treatment in patients with mild to moderate Alzheimer’s Disease.
Disease/Condition: Alzheimer’s disease
Location: Portland
Ages: 55-85
Enrollment Opens: 11/18/2020
Enrollment Closes: TBD
More info »
ATH-1017-Treatment in patients with Parkinson’s Disease Dementia or DLB (Dementia with Lewy Bodies)
Disease/Condition: Parkinson’s Disease Dementia or Dementia with Lewy Bodies (DLB)
Location: Portland
Ages: 40-85
Enrollment Opens: 03/21/2022
Enrollment Closes: TBD
More info »
Phase II Diabetic Macular Edema Study
Disease/Condition: Diabetic Macular Edema
Location: Eugene
Ages: 18+
Enrollment Opens: 12-01-2021
Enrollment Closes: TBD
More info »
Phase II Diabetic Macular Edema Study
Disease/Condition: Diabetic Macular Edema
Location: Eugene
Ages: 18+
Enrollment Opens: 12-01-2021
Enrollment Closes: TBD
More info »
Phase 2/3 Diabetic Macular Edema Trial
Disease/Condition: Diabetic Macular Edema
Location: Eugene
Ages: 18-85
Enrollment Opens: 11-01-2021
Enrollment Closes: TBD
More info »
Phase II Geographic Atrophy from Dry Age-Related Macular Degeneration Study
Disease/Condition: Age-Related Macular Degeneration
Location: Eugene
Ages: 55+
Enrollment Opens: 09-01-2021
Enrollment Closes: TBD
More info »
Phase 3 Wet Age-Related Macular Degeneration Study
Disease/Condition: Age-Related Macular Degeneration
Location: Eugene
Ages: 50+
Enrollment Opens: 05-01-2021
Enrollment Closes: TBD
More info »
Phase II Diabetic Macular Edema Study
Disease/Condition: Diabetic Macular Edema
Location: Eugene
Ages: 18+
Enrollment Opens: 12-01-2021
Enrollment Closes: TBD
More info »
A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children and Young Adults.
Disease/Condition: SARS-COV-2
Location: Gresham
Ages: 6M – 5 years of age
Enrollment Opens: 04-25-2022
Enrollment Closes: TBD
More info »
A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Moderate to Severe Atopic Dermatitis in Children and Adults
Disease/Condition: Atopic Dermatitis
Location: Gresham
Ages: 2 years and above
Enrollment Opens: 11-23-2021
Enrollment Closes: TBD
More info »
An Open-Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Tapinarof Cream 1% in Subjects with Atopic Dermatitis
Disease/Condition: Atopic Dermatitis
Location: Gresham
Ages: 2 years of age and above
Enrollment Opens: 04-29-2022
Enrollment Closes: TBD
More info »
Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents
Disease/Condition: Bacterial Meningitis, MenABCWY combination vaccine
Location: Gresham
Ages: 11-14 years + 364 days
Enrollment Opens: 02-01-2022
Enrollment Closes: TBD
More info »
A Maximum Use (MUsT) Pediatric Study of 1.5% Ruxolitinib Cream in Children (Ages ≥ 2 Years to < 12 Years) With Atopic Dermatitis
Disease/Condition: Atopic Dermatitis
Location: Gresham
Ages: 2-12 years of age
Enrollment Opens: 11-28-2021
Enrollment Closes: TBD
More info »
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages ≥ 2 Years to < 12 Years) With Atopic Dermatitis
Disease/Condition: Atopic Dermatitis
Location: Gresham
Ages: 2 – 12 years of age
Enrollment Opens: 09-22-2021
Enrollment Closes: TBD
More info »
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects with Atopic Dermatitis
Disease/Condition: Atopic Dermatitis
Location: Gresham
Ages: 6-17 years of age and >18
Enrollment Opens: 04-08-2021
Enrollment Closes: TBD
More info »
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis
Disease/Condition: Atopic Dermatitis
Location: Gresham
Ages: 2 years and older
Enrollment Opens: 07-29-2021
Enrollment Closes: TBD
More info »
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis
Disease/Condition: Atopic Dermatitis
Location: Gresham
Ages: 2-5 years of age
Enrollment Opens: 06-30-2021
Enrollment Closes: TBD
More info »
Double-blind, Placebo-controlled and Long-term Study Evaluating the Efficacy and Safety of Prucalopride in Pediatric Subjects with Functional Constipation
Disease/Condition: Functional Constipation
Location: Gresham
Ages: 6 months – 17 years
Enrollment Opens: 07-07-2021
Enrollment Closes: TBD
More info »
A Urine Sample Collection Study in Apparently Healthy Adults and Adults with Chronic, Stable Morbidities
Disease/Condition: Urine Sample Collection Study
Location: Gresham
Ages: 21 – >75
Enrollment Opens: 03-17-2022
Enrollment Closes: TBD
More info »
Clinical Validation of the Healgen Rapid COVID-19 Antigen Test using Subject or Healthcare Provider Collected Nasal Samples for Point-of-Care Use
Disease/Condition: COVID-19 Antigen Test
Location: Gresham
Ages: 2 years of age and older
Enrollment Opens: TBD
Enrollment Closes: TBD
More info »
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to < 18 years of age
Disease/Condition: SARS-COV-2
Location: Gresham
Ages: 12-18 years of age
Enrollment Opens: 05-30-2022
Enrollment Closes: TBD
More info »
A Phase 2, Randomized, Double-blind, Multi-dose, Dose Finding Study to Assess Safety, Tolerability and Immunogenicity of ASP3772, a Multi-valent Pneumococcal Vaccine, in Healthy Infants in Comparison to PCV13
Disease/Condition: Pneumococcal Vaccine
Location: Gresham
Ages: 6 to 13 weeks of age
Enrollment Opens: 06-15-2022
Enrollment Closes: TBD
More info »
A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention
Disease/Condition: Migraine Headache
Location: Portland
Ages: 18+
Enrollment Opens: 07/21/2021
Enrollment Closes: TBD
More info »
Moderate-to-Severe Psoriasis Study
Disease/Condition: Psoriasis
Location: Portland
Ages: 18+
Enrollment Opens: 02-22-2022
Enrollment Closes: TBD
More info »
Moderate-to-Severe Hidradenitis Suppurativa Study
Disease/Condition: Hidradenitis Suppurativa
Location: Portland
Ages: 18+
Enrollment Opens: 03-02-2022
Enrollment Closes: TBD
More info »
Moderate-to-Severe Eczema for Children
Disease/Condition: Eczema
Location: Portland
Ages: 2-17
Enrollment Opens: 09-22-2021
Enrollment Closes: TBD
More info »
Mild-to-Severe Atopic Dermatitis
Disease/Condition: Eczema
Location: Portland
Ages: 18-75
Enrollment Opens: 01-24-2022
Enrollment Closes: TBD
More info »
Mild-to-Moderate Eczema for Children
Disease/Condition: Eczema
Location: Portland
Ages: 6-17
Enrollment Opens: 03-21-2021
Enrollment Closes: TBD
More info »
Moderate-to-Severe Eczema for Adults
Disease/Condition: Eczema
Location: Portland
Ages: 18-74
Enrollment Opens: 03-21-2022
Enrollment Closes: TBD
More info »
COVID-19/Flu A&B Antigen Combo Home Test Study
Disease/Condition: COVID 19/Flu A&B
Location: Gresham
Ages: 2 years of age and older
Enrollment Opens: 03-06-2023
Enrollment Closes: TBD